Semax

Semax was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in the 1980s. The base sequence — Met-Glu-His-Phe, corresponding to ACTH(4-7) — was found to have nootropic properties without ACTH's hormonal effects (cortisol stimulation). The Pro-Gly-Pro extension increases enzymatic stability, extending biological half-life from minutes to hours and making intranasal delivery practical. Semax is registered as a pharmaceutical in Russia (trade name Semax) and is approved for stroke rehabilitation, transient ischemic attacks, and attention deficit disorders in children. Its regulatory history in Russian medicine provides a more established clinical context than most research peptides, though Western regulatory bodies have not reviewed it. The compound's primary mechanism of interest — BDNF (brain-derived neurotrophic factor) upregulation — has made it one of the most scientifically followed nootropic peptides. BDNF is essential for neuronal survival, synaptic plasticity, and long-term potentiation (the cellular basis of memory formation). Compounds that reliably increase BDNF are of significant interest in both performance and neuroprotection contexts.

BDNF elevation is Semax's most scientifically significant documented effect. Studies have shown meaningful increases in BDNF mRNA and protein in brain tissue following Semax administration, which translates to improved neuronal health, synaptic plasticity, and the cellular substrate for learning and memory. Cognitive enhancement — including improved focus, working memory, and mental processing speed — is consistently reported in both Russian clinical studies (cognitive impairment populations) and healthy user anecdotal reports. The effects are described as "clean" cognitive enhancement without the edginess of stimulants. Neuroprotection from ischemic injury has been demonstrated in animal stroke models and clinical settings (Russian medical use post-stroke). Semax appears to reduce neuronal death in ischemia and may improve recovery outcomes in acute cerebrovascular events. Dopamine and serotonin system modulation contributes to mood enhancement and motivation improvement alongside cognitive effects, distinguishing Semax from purely nootropic compounds.

Irritability and anxiety at higher doses are the most commonly reported adverse effects. Some users find that Semax's dopaminergic and stimulatory properties cause an overstimulated, anxious state at doses above their individual threshold. This is manageable by dose reduction and often the rationale for pairing Semax with Selank. Sleep disruption can occur if Semax is taken too late in the day. Morning-only administration is standard practice. Nasal irritation from daily intranasal use, including mild rhinitis or nasal dryness, is reported by some users. Appetite suppression — a modest effect at standard doses — may require attention in users with already low caloric intake.

Nasal spray (most common): 200–900 mcg/day, administered in the morning (and sometimes midday). A typical protocol is 200–300 mcg per nostril, 1–2 times daily, with the last dose no later than early afternoon to prevent sleep disruption. Injection (SubQ): 50–300 mcg per injection, 1–2 times daily. The injectable route bypasses nasal cavity variability and may provide more consistent dosing. N-Acetyl Semax (NA-Semax): A modified form with an acetyl group that some users prefer for improved lipophilicity and potentially enhanced CNS penetration. Cycles: Courses of 2–4 weeks are common, followed by equal or longer breaks. Tolerance to Semax's cognitive effects has been reported with continuous long-term use.

Russia: Registered pharmaceutical drug. Available through pharmacies. United States: Research chemical — no controlled substance scheduling, no FDA approval. Legal for research purchase. WADA: Not prohibited.

Semax + Selank: The canonical Russian peptide nootropic stack. Semax provides cognitive stimulation and BDNF upregulation; Selank provides anxiolysis to counterbalance any Semax-driven anxiety and adds its own complementary nootropic effects. Semax + racetams: Some nootropic users combine Semax with piracetam or aniracetam for additional cholinergic enhancement alongside Semax's neurotrophin and dopaminergic effects. Semax + BPC-157: A recovery-focused protocol combining neuroprotection (Semax) with systemic healing (BPC-157), used by some practitioners for cognitive recovery after brain injury or neurological stress.

Semax — Common Questions